**3.2 Adverse events associated with PARPis and management**

The adverse events of PARPi are largely class effects and are well-characterized. The following section describes the most frequently observed adverse events in PARPi as a class, health care professionals (HCP) should always refer to the latest prescribing information or product information for further adverse event-related recommendations.

## *3.2.1 Fatigue*

Fatigue/asthenia of any grade is one of the most common class-wide adverse events of PARPis reported in 50–70% of patients in various treatment settings. Dose interruption or dose reduction may be utilized to manage fatigue/asthenia symptoms in 3–13% of patients
